Twentieth Anniversary of Leptin discovery and the Approval of Myalept by FDA

Ata Mahmoodpoor, Javad Mahmoudi, Saeed Sadigh-Eteghad, Babak Sabermarouf*, Samad EJ Golzari

1. Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2. Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran
3. Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Leptin is a 16 kDa hormone that is mainly expressed in adipose tissues (1). The major target of leptin is hypothalamus and it suppresses food intake and energy consumption, consequently diminishing adipose deposits and body weight (2, 3). The OB gene was isolated by Friedman in 1994 (4). Based on the suggestion of Roger Guillemin, Friedman named this new hormone "leptin" from the Greek lepto meaning thin (5, 6).

Since leptin discovery, numerous studies have been conducted on its physiological effects and its function in pathological conditions. Most of studies on leptin concentrated on its metabolic actions (7), receptors (8) and further broad functions such as immunity modulation (9) and memory processing (10). Considering such a vast range of functions, it is clear that patients with lack of leptin physiologically need pharmacological interventions.

At this moment, we are in the twentieth year of leptin discovery. Finally, FDA approved a drug named Myalept (metreleptin for injection) on February 2014 to treat rare metabolic disease caused by leptin deficiency.

Congenital generalized lipodystrophy is a disorder with partial lack of fat tissues (11). The trial for the safety and effectiveness of Myalept demonstrated decrease in HbA1c, fasting blood glucose, and triglycerides (11). Nevertheless, there are some limitations to the usage of Myalept in HIV-related lipodystrophy and some metabolic disorders (11). Moreover, it may increase the risk of lymphoma by producing anti-metreleptin antibodies neutralizing endogenous leptin.

Considering these concerns, Myalept is available only through a limited profile under a Risk Evaluation and Mitigation Strategy (REMS). Myalept is contraindicated in patients with general obesity not related to congenital leptin deficiency (12).

Even though, Myalept has very limited indications for use in general population, it is considered a milestone towards the discovery of novel treatments for Leptin deficiencies and disorders.

Future investigations are necessary for the discovery of unknown aspects of Myalept therapy and production of new leptin-based...
agents for treatment of a wide spectrum of diseases.

**Keywords:** Leptin; Myalept; Obesity;

**References**